Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer.
Saved in:
| Title: | Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. |
|---|---|
| Authors: | Weiner AB; Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA; Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA. Electronic address: abweiner@mednet.ucla.edu., Agrawal R; Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA; Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Wang NK; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA; Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Sonni I; Department of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA; Department of Clinical and Experimental Medicine, University Magna Graecia, Catanzaro, Italy., Li EV; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Arbet J; Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA; Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA; Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Zhang JJH; Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Proudfoot JA; Veracyte, Inc, San Diego, CA, USA., Hong BH; Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore., Davicioni E; Veracyte, Inc, San Diego, CA, USA., Kane N; Department of Radiation Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA; Radiation Oncology Service, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA., Valle LF; Department of Radiation Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA; Radiation Oncology Service, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA., Kishan AU; Department of Radiation Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Pra AD; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA., Ghadjar P; Department of Radiation Oncology, Charité Universitätsmedizin Berlin, Berlin, Germany., Sweeney CJ; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, SA, Australia., Nickols NG; Department of Radiation Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA; Radiation Oncology Service, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA., Karnes RJ; Department of Urology, Mayo Clinic, Rochester, MN, USA., Shen J; Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA; Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Rettig MB; Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA; Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Czernin J; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Ross AE; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Lee Kiang Chua M; Divisions of Radiation Oncology and Medical Sciences, National Cancer Centre, Singapore, Singapore; Duke-NUS Medical School, Singapore, Singapore., Schaeffer EM; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Calais J; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Boutros PC; Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA; Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA; Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA., Reiter RE; Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA. |
| Source: | European urology [Eur Urol] 2024 Dec; Vol. 86 (6), pp. 579-587. Date of Electronic Publication: 2024 Sep 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Science Country of Publication: Switzerland NLM ID: 7512719 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7560 (Electronic) Linking ISSN: 03022838 NLM ISO Abbreviation: Eur Urol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
